Major Depressive Disorder

Roughly 41% of those diagnosed with psychiatric illness were also smokers, and they were 70% more likely to be smokers than their counterparts without psychiatric illness.

Following decades of research prohibition, physicians are once again raising the psilocybin question. This time, they’re letting data define the answer.

A new review of the scientific literature suggests there’s ample evidence over-the-counter painkillers have psychological effects.

Physician suicide is a taboo topic—and despite high rates of depression and PTSD among doctors, little help exists for those at risk.

The rate of reward center volume loss may vary between nondepressed individuals and depressed individuals across multiple age groups.

Transcranial magnetic stimulation, which was approved by the FDA for drug-resistant depression in 2009, has recently experienced a growth in clinical use.

During perimenopause, women are more likely to experience symptoms of depression, and during postmenopause, they are more likely to experience anxiety symptoms.

A new study suggests the novel therapy can help empower patients with psychoses.

Steve Levine, MD, discussed the challenges physicians must overcome when treating patients with major depressive disorder.

Work-related sick leave dropped 18% for employees working for managers that received mental health training.

Results determined that 168 out of the 300 patients, or 56.0%, had felt "some type of anxiety" related to the anti-VEGF treatments.

Psychedelics like psilocybin have been receiving attention from psychiatrists on and off for decades. Here's what we've learned, and what's on the horizon.

Parental rejection, abandonment, physical and sexual abuse double the victim's rates of depression, inflammation, metabolic disorders and chronic medical illnesses.

Using 24-hour wrist monitors, the study revealed “distinct mood-dependent effects on wrist-activity markers of circadian timekeeping.”

In a phase 2 trial, MDMA reduced PTSD in 68% of patients after a 12-months period.

These tools can reduce selection bias and misdiagnosis, and improve communication between primary and secondary care physicians.

12% of patients prescribed the 2 drugs in combination were still taking benzodiazepine 6 months later.

Though safer for relapsing-remmitting multiple sclerosis than new disease-modifying therapies, the treatment nearly doubles the chance of a patient suffering from a stroke.

The survey applied a validated questionnaire to distinguish drug treatment side effects from the symptoms of major depression.